BRKR 📈 Bruker - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1167941087
BRKR: Scientific Instruments, Analytical Solutions, Diagnostic Tools, Microscopy Systems
Bruker Corporation is a leading developer, manufacturer, and distributor of scientific instruments, analytical, and diagnostic solutions, operating across the globe, including the United States, Europe, the Asia Pacific, and other international markets. The company's diverse product portfolio is organized into four main segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies, each catering to distinct needs within the scientific community. Its life science tools and single and multiple modality systems are designed to support various research and diagnostic applications, including life science mass spectrometry and the MALDI Biotyper platform for rapid pathogen identification.
The company's diagnostic solutions include a range of molecular diagnostics kits, such as genotype and fluorotype kits, as well as specific products for the diagnosis of COVID-19, like the Fluorotyper-SARS-CoV-2 plus kits. Furthermore, Bruker offers a variety of analytical and detection systems, including portable and handheld options, X-ray fluorescence spectrometry instruments, and atomic force microscopy instrumentation. These tools are crucial for research, analytical, and process analysis across different fields, providing high-resolution imaging and analysis capabilities. The non-contact nanometer resolution solution topography and automated X-ray metrology, along with AFM defect-detection and photomask repair and cleaning equipment, underscore the company's commitment to advancing technological capabilities in scientific research and industrial applications.
Bruker's product lineup also encompasses advanced optical fluorescence microscopy instruments, designed to support the complex needs of researchers in translational research, drug discovery, and biomarker identification. The company's involvement in superconducting materials and devices, including metallic low-temperature superconductors, reflects its role in cutting-edge technological development. Additionally, Bruker provides non-superconducting high-technology tools, such as synchrotron and beamline instrumentation, further solidifying its position as a comprehensive solutions provider for the scientific and research communities. With its incorporation in 1991 and headquarters in Billerica, Massachusetts, Bruker Corporation has established itself as a significant player in the life sciences tools and services sector, with its common stock listed under the ISIN US1167941087 and categorized under the GICS Sub Industry: Life Sciences Tools & Services.
Additional Sources for BRKR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BRKR Stock Overview
Market Cap in USD | 8,668m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2000-08-04 |
BRKR Stock Ratings
Growth 5y | 5.88% |
Fundamental | 15.1% |
Dividend | 50.7% |
Rel. Strength Industry | -516 |
Analysts | 4.07/5 |
Fair Price Momentum | 46.71 USD |
Fair Price DCF | 26.74 USD |
BRKR Dividends
Dividend Yield 12m | 0.35% |
Yield on Cost 5y | 0.39% |
Annual Growth 5y | 4.56% |
Payout Consistency | 96.7% |
BRKR Growth Ratios
Growth Correlation 3m | -72.4% |
Growth Correlation 12m | -81.2% |
Growth Correlation 5y | 45.3% |
CAGR 5y | 2.25% |
CAGR/Mean DD 5y | 0.11 |
Sharpe Ratio 12m | -0.59 |
Alpha | -47.88 |
Beta | 0.97 |
Volatility | 40.99% |
Current Volume | 3337.9k |
Average Volume 20d | 1501k |
As of December 21, 2024, the stock is trading at USD 57.00 with a total of 3,337,883 shares traded.
Over the past week, the price has changed by -1.26%, over one month by +6.89%, over three months by -15.53% and over the past year by -21.43%.
Neither. Based on ValueRay Fundamental Analyses, Bruker is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 15.09 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BRKR as of December 2024 is 46.71. This means that BRKR is currently overvalued and has a potential downside of -18.05%.
Bruker has received a consensus analysts rating of 4.07. Therefor, it is recommend to buy BRKR.
- Strong Buy: 6
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BRKR Bruker will be worth about 51.2 in December 2025. The stock is currently trading at 57.00. This means that the stock has a potential downside of -10.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 74.2 | 30.1% |
Analysts Target Price | 77.8 | 36.5% |
ValueRay Target Price | 51.2 | -10.2% |